Dandiss Tech Co.,Ltd

Dandiss technology CO.,LTD is a fast-growing biopharmaceutical company that engages in the research, development and manufacturing of Active Pharmaceutical Ingredients and Intermediates with primary focus on the high-end API market and late-stage drug candidates. The Company has achieved revenue growth rate of over 100% annually since its establishment in 2001. It has been rewarded research grants by the Ministry of Science and Technology for innovative breakthroughs in a number of patented pharmaceutical intermediates. Headquartered in the Center for New Medicine Discovery and Research in Hangzhou , BrightGene is aggressively committed to the commercialization of the following leading products in its rapidly expanding pipeline: Entecavir and intermediates Posaconazole intermediates Fondaparinux sodium intermediate Lapatinib intermediates Pemetrexed disodium and intermediates Aliskiren intermediates In addition, our commitment extends to delivering excellent products and services for clients around the globe and partnering with companies and institutions whose strength will augment our own. API and API's intermediate Fondaparinux sodium Aliskiren hemifumarate Alvimopan Entecavir monohydrate Argatroban Caspofungin Posaconazole Pemetrexed disodium Telaprevir Boceprevir Latamoxef sodium Sitagliptin Ticagrelor Bortezomib Aprepitant Fosaprepitant Conjugated Estrogens Sulfadoxine Ebastine Cilnidipine Spironolactone Standard material standard of plant extracts standard of drug standard of drug's impurity Plant extracts Nobiletin Andrographolide Kaempferol Ursolic acid Oleanolic acid Fisetin Rutin trihydrate Hyperoside Myricetin